CD74 and melanoma: The therapeutic implications of tumour-specific MHC-II (tsMHC-II) are promising, wherein their upregulation correlates with a better response to an anti-PD-1 monoclonal antibody in Hodgkin lymphoma and melanoma [12,36], and therefore offering opportunities as a biomarker in the development of immunotherapies [13,25].